$HZNP - On our trading list. having a great month. More analyst comments today.Horizon Pharma price target raised to $40 from $35 at JefferiesJefferies analyst David Steinberg increased his price target on Horizon Pharma shares to $40 from $35 after an FDA advisory committee voted 12-0 that the benefits of teprotumumab outweigh the potential risks in treating thyroid eye disease, or TED. While acknowledging that the FDA is not bound by this recommendation, Steinberg sees it as "a strong signal" for approval ahead of the drug's March 8, 2020 PDUFA action date, he tells investors. He keeps a Buy rating on Horizon shares.Horizon Pharma price target raised to $40 from $35 at StifelStifel analyst Annabel Samimy raised her price target for Horizon Pharma to $40 from $35 citing an FDA panel's unanimous vote recommending approval of teprotumumab. Overall, teprotumumab approval seems unquestionable, with discussions leading to a conclusion of allowing maximum access to finally give thyroid eye disease patients a real option, Samimy tells investors in a research note. She keeps a Buy rating on Horizon Pharma shares.Horizon Pharma price target raised to $40 from $36 at BMO CapitalBMO Capital analyst Gary Nachman raised his price target on Horizon Pharma to $40 and kept his Outperform rating after the favorable unanimous FDA vote on teprotumumab. The panelists recognized the drug's "outstanding efficacy for a devastating disease with very high unmet need" and he believes the company's key marketed product Krystexxa and key pipeline product Teprotumumab will be sources of upside going forward, Nachman tells investors in a research note. $HZNP, Horizon Therapeutics Public Limited Company / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page